Skip to main content
MedVellum
QuestionsVideosPricing

MedVellum

Fellowship exam preparation across every specialty: source-verified topics, questions in every format, and videos.

Product

  • Specialties
  • Questions
  • Videos
  • Exam tools
  • Pricing

Verification & policy

  • Verified register
  • Editorial policy
  • Privacy
  • Terms

Account

  • Sign in
  • Create account
  • Dashboard
  • Account & billing

© 2026 MedVellum. For education only — not a substitute for clinical judgement.

llms.txtPsychiatry LLM catalogSitemap

GP KFPs / SAQspalliative-care

GP KFPs / SAQs · palliative-care

Palliative symptom control in the community — KFP-style written assessment

KFP-style staged scenarios on palliative symptom control: opioid selection by renal function, breakthrough dosing calculation, antiemetic selection by receptor mechanism, laxative co-prescribing, terminal agitation management, and syringe driver initiation.

30 marks45 min2 min readVerification in progress

Target exams

RACGP KFPRACGP AKTMRCGP AKT
On this page
Study tools

Target exams

RACGP KFPRACGP AKTMRCGP AKT
Prompt
Palliative symptom control: match the opioid to the kidney, calculate the breakthrough dose, select the right antiemetic, and never forget the laxative

KFP 1 (10 marks)

A 62-year-old woman with metastatic breast cancer has moderate-to-severe pain. Her eGFR is 22 mL/min. She is currently on paracetamol alone. [1]

  1. Which opioid class should you avoid and why? (4) [1]
  2. What should you prescribe instead? (3) [1]
  3. What breakthrough dose rule applies? (3)

Model answers

  1. Avoid morphine and codeine. Morphine produces active metabolites M6G (analgesic) and M3G (neuroexcitatory) that are cleared renally; at eGFR 22 they accumulate causing sedation, myoclonus and respiratory depression. Codeine is also renally cleared with active metabolites. [1]
  2. Prescribe a fentanyl patch for background analgesia plus low-dose subcutaneous fentanyl PRN for breakthrough. Buprenorphine patch is an alternative. Both undergo hepatic metabolism without active renally-cleared metabolites. [1]
  3. Breakthrough dose equals one-sixth of the total 24-hour opioid dose, given PRN by the same route. Two or more PRN doses in 24 hours means the background dose should be increased. [1]
General Practice Pro

Continue reading

You have read the opening of this kfps / saq. The complete unit — every section and its primary-source references — is part of the General Practice fellowship library.

Sign in to continueSee pricing
References4ShowHide
  1. [1]King S, Forbes K, Hanks GW, Ferro CJ, Chambers EJ A systematic review of the use of opioid medication for those with moderate to severe cancer pain and renal impairment: a European Palliative Care Research Collaborative opioid guidelines project. Palliat Med, 2011.PMID 21708859
  2. [2]Chamberlain BH, Rhiner M, Slatkin NE, Stambler N, Israel RJ Methylnaltrexone Treatment for Opioid-Induced Constipation in Patients with and without Cancer: Effect of Initial Dose. J Pain Res, 2023.PMID 37533563
  3. [4]Smallwood NE, Pascoe A, Wijsenbeek M, Russell AM, Holland AE, et al. Opioids for the palliation of symptoms in people with serious respiratory illness: a systematic review and meta-analysis. Eur Respir Rev, 2024.PMID 39384304
  4. [5]Pereira RA, Barcellos G, Lenz G, Christmann A, de Mello MAJ, et al. Fan Therapy for Dyspnea in Palliative and Supportive Care: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Respir Care, 2026.PMID 41761933
General Practice Pro

$29/ monthor $279 / year

The complete General Practice library, every exam format, one subscription.

  • Complete library for one chosen specialty
  • Timed MCQ mock exams and spaced review
  • Clinical cases & cross-table vivas
See pricingSign in
PreviousType 2 diabetes — KFP-style written assessmentmetabolic-and-endocrine-healthNextProcedural scope in rural general practice — KFP-style written assessmentrural-health